微信小陈
微信小章| 产品名称： | Panc 04.03 |
|---|---|
| 商品货号： | TS152940 |
| Organism： | Homo sapiens, human |
| Tissue： | pancreas |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | adenocarcinoma |
| Age： | 70 years adult |
| Gender： | male |
| Ethnicity： | White |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Panc 04.03 is a pancreatic adenocarcinoma epithelial cell line derived, in 1995, from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma. |
| Clinical Data： | 70 years
Caucasian
male |
| Antigen Expression： | MHC class I +; MHC class II - Ref   Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602Blood type O; Rh+ |
| Oncogene： | K-ras +
RefJaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| Genes Expressed： | cytokeratins 7 and 18xa0Ref Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| Cellular Products： | cytokeratins 7 and 18
Ref Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| Tumorigenic： | Yes |
| Effects： | Yes, forms tumors in nude or SCID mice |
| Comments： | The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine.xa0Ref The cells have a reported plating efficiency of 80%.xa0Ref |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
|
| Subculturing： | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subcultivation Ratio: 1:2 to 1:3 xa0 Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a Manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994. |
| Cryopreservation： | Complete growth medium supplemented with 5% (v/v) DMSO. Cell culture tested DMSO is available as ATCC Catalog No. 4-X.
|
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| STR Profile： | Amelogenin: X CSF1PO: 12 D13S317: 11,12 D16S539: 11,12 D5S818: 11 D7S820: 8,12 THO1: 9.3 TPOX: 10,11 vWA: 14,16 |
| Population Doubling Time： | 50.5 hrs |
| Name of Depositor： | EM Jaffee |
| Deposited As： | human |
| Year of Origin： | April 3, 1995 |
| References： | Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |